Analysis of the effectiveness and safety of maintenance treatment with intravenous ustekinumab in inflammatory bowel disease.

Background And Purpose Of The Study: Ustekinumab is a monoclonal antibody approved for the treatment of moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). In spite of being an effective treatment, patients may have suboptimal response, or lose it over time. In these cases, ustekinumab intravenous (IV) maintenance therapy has been explored as a rescue option.